1[1]Cleland JGF, Swedberg K, Poole - Wilson PA. Successes and failures of current treatment of heart failure[J].Lancet, 1998, 352(suppl): 19 - 28
2[2]Packer M, Bristow MR, Cohn IN, et al. Effect of Carvedilol on marbidity and mortality in chronic heart failure[J ]. N Engl J Med, 1996, 334:1349 - 1355
3[3]Francis GS, Mcdonald K M, Mrepi MB, et al. Neurohormonal activation in preclinical heart failure:Remodeling and potential for intervention[ J ]. Circulation, 1993, 87(suppl Ⅳ ): Ⅳ - 90
4[4]Ruffolo RR Jr, Feuerstein GZ, Ohistein EH. Recent observations with β- adrenocepter blockade - Beneficial effects in hypertension and heart failure[J]. Am J Hypertens, 1998, 11:9 - 14
6[1]CIBIS-Ⅱ Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study Ⅱ (CIBIS Ⅱ): a randomized trial. Lancet, 1999,353: 9-13.
7[2]MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353:2001-2007.
8[3]Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001,344:1651-1658.
9[5]Packer M, Cohn JN, Abraham WT, et al. Consensus recommendations for management of chronic heart failure. Am J Cardiol, 1999, 83:1A-38A.
10[6]Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treartment of chronic heart failure. Eur Heart J,2001, 22:1527-1560.
